Literature DB >> 15030301

Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders.

Clive R Pullinger1, John P Kane, Mary J Malloy.   

Abstract

Coronary heart disease is a major cause of death in Europe and the USA. Insudation of atherogenic lipoproteins, including low-density lipoprotein (LDL), into the artery wall is integral to atherosclerosis. It is clear that numerous genetic loci contribute to increased plasma levels of LDL. However, five specific monogenic disorders, three of which have been reported recently, are known to increase LDL. These are familial hypercholesterolemia (LDL receptor gene: LDLR); familial ligand-defective apoB- 100 (apoB gene: APOB); autosomal recessive hypercholesterolemia (ARH gene); sitosterolemia (ABCG5 or ABCG8 genes) and cholesterol 7alpha-hydroxylase deficiency (CYP7A1 gene). This review relates the mechanisms underlying these five disorders with specific therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15030301     DOI: 10.1586/14779072.1.1.107

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  9 in total

1.  Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease.

Authors:  Fanggeng Zou; Rangaraj K Gopalraj; Johann Lok; Haiyan Zhu; I-Fang Ling; James F Simpson; H Michael Tucker; Jeremiah F Kelly; Samuel G Younkin; Dennis W Dickson; Ronald C Petersen; Neill R Graff-Radford; David A Bennett; Julia E Crook; Steven G Younkin; Steven Estus
Journal:  Hum Mol Genet       Date:  2007-12-08       Impact factor: 6.150

2.  Management of Hyperlipidemia in the Pediatric Population.

Authors:  Serena Tonstad; Gilbert R. Thompson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-10

3.  A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol.

Authors:  Haiyan Zhu; H Michael Tucker; Karrie E Grear; James F Simpson; Alisa K Manning; L Adrienne Cupples; Steven Estus
Journal:  Hum Mol Genet       Date:  2007-05-21       Impact factor: 6.150

Review 4.  Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes.

Authors:  John D Baxter; Paul Webb
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

5.  Accounting for a quantitative trait locus for plasma triglyceride levels: utilization of variants in multiple genes.

Authors:  Lisa J Martin; Ahmed H Kissebah; Michael Olivier
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

6.  Variable expressivity and co-occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy.

Authors:  Akl C Fahed; Ruby Khalaf; Rony Salloum; Rabih R Andary; Raya Safa; Inaam El-Rassy; Elie Moubarak; Sami T Azar; Fadi F Bitar; Georges Nemer
Journal:  Mol Genet Genomic Med       Date:  2016-02-24       Impact factor: 2.183

7.  Three patients with homozygous familial hypercholesterolemia: Genomic sequencing and kindred analysis.

Authors:  Karen H Y Wong; Michal Levy-Sakin; Walfred Ma; Nina Gonzaludo; Angel C Y Mak; Dedeepya Vaka; Annie Poon; Catherine Chu; Richard Lao; Melek Balamir; Zoe Grenville; Nicolas Wong; John P Kane; Pui-Yan Kwok; Mary J Malloy; Clive R Pullinger
Journal:  Mol Genet Genomic Med       Date:  2019-10-16       Impact factor: 2.183

8.  Functional genomic and epidemiological studies reveal novel genes regulating cholesterol metabolism.

Authors:  Kris Richardson; Jose M Ordovas
Journal:  Genome Med       Date:  2009-10-27       Impact factor: 11.117

Review 9.  Diagnosis and Management of Sitosterolemia 2021.

Authors:  Hayato Tada; Akihiro Nomura; Masatsune Ogura; Katsunori Ikewaki; Yasushi Ishigaki; Kyoko Inagaki; Kazuhisa Tsukamoto; Kazushige Dobashi; Kimitoshi Nakamura; Mika Hori; Kota Matsuki; Shizuya Yamashita; Shinji Yokoyama; Masa-Aki Kawashiri; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-04-28       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.